Overview
CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2022-09-01
2022-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treatment of hereditary angioedemaPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
CSL BehringTreatments:
Antibodies, Monoclonal
Criteria
Inclusion Criteria:- Male or female ≥ 12 years of age; diagnosed with clinically confirmed C1-INH
hereditary angioedema; experience ≥ 3 attacks during the 3 months before screening
Exclusion Criteria:
- Concomitant diagnosis of another form of angioedema such as idiopathic or acquired
angioedema, recurrent angioedema associated with urticarial or hereditary angioedema
type 3